Stock comparison
Merck & Co., Inc. is 19.0x more valuable than GENMAB A/S by market capitalization ($308.90 B vs $16.27 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 19.0x more valuable than GENMAB A/S by market capitalization ($308.90 B vs $16.27 B).
Market value leader
MRK
Merck & Co., Inc. is 19.0x more valuable than GENMAB A/S by market capitalization ($308.90 B vs $16.27 B).
| Metric | GMAB | MRK |
|---|---|---|
| Market cap | $16.27 B | $308.90 B |
| US-listed rank | #694 | #45 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | - | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.9x |
| SEC filings | 540 | 998 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 19.0x more valuable than GENMAB A/S by market capitalization ($308.90 B vs $16.27 B).
Full pages: GENMAB A/S and Merck & Co., Inc., or browse the full rankings.